GlassScriptPhysician profile
Jacob Mark Burdett
NPI 1104366574
$3,454.97
in general payments reported to CMS, 2019-2025
16 companies · $903 in 2025
The $903 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $168 · 2021: $204 · 2022: $518 · 2023: $1,083 · 2024: $227 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Travel and Lodging: $661 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.47 |
| Travel and Lodging | $661.08 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $978.85 | 2023-2025 | Inspire |
| Optinose US, INC. | $471.19 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $450.43 | 2019-2025 | Dupixent |
| Stryker Corporation | $348.68 | 2023-2025 | Scopis Ent, Na, Core |
| Integra Lifesciences Corporation | $233.71 | 2021-2025 | Tenoglide, Trudi Probe, Inspira Air |
| Medtronic, INC. | $187.50 | 2022-2025 | Stealthstation S8 Platform, Propel |
| Intersect Ent, INC. | $171.05 | 2019-2020 | |
| Genzyme Corporation | $151.63 | 2022-2025 | |
| Glaxosmithkline, LLC. | $102.49 | 2025 | Nucala |
| Olympus America INC. | $79.45 | 2024 | Rhino-Laryngo Videoscope |
| Abbott Laboratories | $68.89 | 2024-2025 | Freestyle Libre 3 |
| Cochlear Americas | $57.30 | 2019-2025 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Polynovo North America LLC | $52.96 | 2024-2025 | Novosorb Btm |
| Smith+Nephew, INC. | $33.33 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $14.52 | 2025 | Tirosint, Licart, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Burdett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.